Allspring Global Investments
CHRS icon

Allspring Global Investments’s Coherus Oncology CHRS Stock Holding History

Allspring Global Investments’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$104 – 1891
2024
Q3 		$104 Buy
+100
New +$137 ﹤0.01% 2425
2024
Q2 		– Sell
-10,446
Closed -$25K – 2402
2024
Q1 		$25K Buy
10,446
+2,201
+27% +$5.42K ﹤0.01% 2069
2023
Q4 		$27.5K Sell
8,245
-31,764
-79% -$85.1K ﹤0.01% 1939
2023
Q3 		$150K Sell
40,009
-2,279
-5% -$10.5K ﹤0.01% 1842
2023
Q2 		$181K Buy
42,288
+4,237
+11% +$25K ﹤0.01% 1844
2023
Q1 		$260K Sell
38,051
-2,596
-6% -$20.1K ﹤0.01% 1753
2022
Q4 		$322K Buy
40,647
+5,496
+16% +$42.3K ﹤0.01% 1713
2022
Q3 		$337K Buy
35,151
+5,632
+19% +$57K ﹤0.01% 1670
2022
Q2 		$213K Sell
29,519
-25,279
-46% -$220K ﹤0.01% 1800
2022
Q1 		$707K Buy
54,798
+1,094
+2% +$13.9K ﹤0.01% 2064
2021
Q4 		$857K Buy
+53,704
New +$939K ﹤0.01% 2032

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Allspring Global Investments's CHRS Position: Q4 2024 in Review

Allspring Global Investments sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 100 shares — an estimated $104 sold.

Allspring Global Investments first reported a position in CHRS in Q4 2021 and held it in 11 quarters. The position peaked at $857K in Q4 2021. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Allspring Global Investments reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 100 Coherus Oncology shares in Q4 2024, an estimated $104.
  • Allspring Global Investments first reported a position in Coherus Oncology in Q4 2021 and held it in 11 quarters.
  • Allspring Global Investments's Coherus Oncology position peaked at $857K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.